Despite the observed acceptable safety profile and immunogenicity, GSK decided to terminate the clinical development of cancer vaccines consisting of recombinant proteins and AS15, considering the negative results of the AS15 adjuvant platform in two phase 3 clinical trials of MAGE‐A3 therapeutics. The gene discussed is MAGEA3; the disease is cancer.